DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
Stock Information for DURECT Corporation
Loading
Please wait while we load your information from QuoteMedia.